Patents by Inventor Niranjana Nagarajan

Niranjana Nagarajan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC ANTIGEN RECEPTORS TARGETING CD70
    Publication number: 20230041456
    Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
    Type: Application
    Filed: June 17, 2022
    Publication date: February 9, 2023
    Inventors: Surabhi SRIVATSA SRINIVASAN, Niranjana NAGARAJAN, Siler PANOWSKI, Yoon PARK, Tao SAI, Barbra SASU, Thomas VAN BLARCOM, Mathilde DUSSEAUX, Roman GALETTO
  • MULTIVALENT REGULATORY T CELL MODULATORS
    Publication number: 20210403579
    Abstract: This disclosure provides compounds that contain an IL-2 receptor-binding domain and an ST2-binding domain, e.g. an antibody or fragment thereof that specifically binds ST2. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding domain and an ST2-binding domain.
    Type: Application
    Filed: October 30, 2019
    Publication date: December 30, 2021
    Applicant: Delinia, Inc.
    Inventors: Jungmin Kim, Niranjana Nagarajan, Jeffrey Greve
  • Multivalent regulatory T cell modulators
    Patent number: 11059877
    Abstract: This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: July 13, 2021
    Assignee: Delinia, Inc.
    Inventors: Jeffrey Greve, Jungmin Kim, Niranjana Nagarajan, John Cho
  • MULTIVALENT REGULATORY T CELL MODULATORS
    Publication number: 20200031897
    Abstract: This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.
    Type: Application
    Filed: October 17, 2019
    Publication date: January 30, 2020
    Applicant: Delinia, Inc.
    Inventors: Jeffrey Greve, Jungmin Kim, Niranjana Nagarajan, John Cho
  • Multivalent regulatory T cell modulators
    Patent number: 10472405
    Abstract: This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: November 12, 2019
    Assignee: Delinia, Inc.
    Inventors: Jeffrey Greve, Jungmin Kim, Niranjana Nagarajan, John Cho
  • MULTIVALENT REGULATORY T CELL MODULATORS
    Publication number: 20180162919
    Abstract: This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 14, 2018
    Applicant: Delinia, Inc.
    Inventors: Jeffrey Greve, Jungmin Kim, Niranjana Nagarajan, John Cho